1. Home
  2. CET vs PGEN Comparison

CET vs PGEN Comparison

Compare CET & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

N/A

Current Price

$55.20

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$6.83

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
PGEN
Founded
1929
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CET
PGEN
Price
$55.20
$6.83
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.33
AVG Volume (30 Days)
31.8K
4.9M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
N/A
$81.04
P/E Ratio
$6.93
$228.67
Revenue Growth
N/A
N/A
52 Week Low
$47.82
$1.80
52 Week High
$55.99
$7.32

Technical Indicators

Market Signals
Indicator
CET
PGEN
Relative Strength Index (RSI) 63.90 67.59
Support Level $52.20 $3.96
Resistance Level N/A N/A
Average True Range (ATR) 0.72 0.41
MACD 0.21 0.08
Stochastic Oscillator 77.74 77.58

Price Performance

Historical Comparison
CET
PGEN

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: